Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,516.00
(
0.29%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Lewis R Goudy post# 12712

Tuesday, 07/08/2008 4:54:21 PM

Tuesday, July 08, 2008 4:54:21 PM

Post# of 19309
Re: CABG/COG (as opposed to CABG/HR)

You raise some good questions, but I don’t think anyone has definitive answers.

If Ovation does decide to pursue CABG/COG (doubtful, IMO, but it can’t be ruled out entirely), one or more phase-2 studies would probably be needed to refine the efficacy endpoints and treatment protocols.

This is in sharp contrast to CABG/HR, where the endpoints and protocols are well-understood and Ovation ought to be able to secure an SPA for a phase-3 trial without having to run any new phase-2 studies.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today